Selpercatinib for previously untreated advanced RET-fusion positive thyroid cancer

Selpercatinib is in clinical development for untreated advanced RET-fusion positive thyroid cancer in adults. Thyroid cancer is a rare form of cancer that originates in the thyroid gland located in the front of the neck. RET is a type of protein called a kinase, which is involved in various cell processes. RET-fusion positive cancer is a type of cancer that is caused by the abnormal re-arrangement of the RET gene, which leads to an overactive process that causes the cancer cells to grow uncontrollably. Furthermore, thyroid cancer cases that are RET-fusion positive often result in harsher symptoms and poorer patient outcomes.